Dr. Enrico Derenzini
hematology and oncology
hematology and oncology
Overview
Country, City
Italy, Milan
Health facility
European Institute of Oncology Milan
Medical unit
Department of oncohematology
About the doctor
Skills & Expertise
lymphoma
leukemia
chemotherapy
cancer
follicular lymphoma
fludarabine
mitoxantrone
stem cell transplantation
lymphoblastic leukemia
ibritumomab
hematology
elderly
brentuximab
nonhodgkin lymphoma
lymphocytic leukemia
umbralisib
peripheral tcell lymphoma
metastases
colorectal cancer
hodgkins lymphoma
tumor
hepatocellular carcinoma
b cell lymphoma
carcinoma
doxorubicin
oncology
liver
large cell lymphoma
bortezomib
cyclophosphamide
arterial infusion
stromal tumor
haematological malignancies
burkitt lymphoma
relapsed lymphoma
lymphoid malignancies
chemotherapyinduced anemia
blood cancer
lymphoproliferative syndromes
myeloblastic leukemia
mantle cell
myeloid neoplasms
indolent lymphoma
plasmablastic lymphoma
lung metastases
colon cancer
hepatic metastases
pancreatic cancer
ovarian cancer
breast cancer
Resume
CV (Curriculum Vitae)
Education
- Studied human medicine
- Obtaining a license for medical practice
- Obtaining specialization in hematology
- 2021-2022 Postgraduate School of Medical Genetics
- 2022-2023 Postgraduate program: “Nutritional support and intervention”
Experience
- Director of the Department of oncohematology at the European Institute of Oncology Milan
- Associate Professor of the Department of health sciences at the University of Milan
Awards & Memberships
- Faculty Member of the European School of Molecular Medicine
- Coordinator of the Italian working group of hematology of the Alliance Against Cancer Network
Languages
English
Italian
Publications
Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.
October, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
22 September, 2023
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
September, 2023
Location
Via Giuseppe Ripamonti, 435, 20141 Milan, Italy
FAQ
Where does the doctor practice?
What is the specialization of Dr. Enrico Derenzini?
The primary specialization of the doctor is hematology and oncology.
What is the rating of the doctor?
Dr. Enrico Derenzini is rated as 9.70 by AiroMedical.
Dr. Enrico Derenzini
Get individual treatment plan and cost estimate. Non-binding 100% free assessment.
© Dr. Enrico Derenzini